What is the level of liabilities of Geron this year?
Geron has a debt balance of 146.13 M USD this year.
Geron Liabilities 2024
Geron Liabilities
146.13 M USD
Ticker
GERN
ISIN
US3741631036
WKN
902213
In 2024, Geron's total liabilities amounted to 146.13 M USD, a 32.12% difference from the 110.6 M USD total liabilities in the previous year.
Geron Aktienanalyse
What does Geron do?
Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Geron's Liabilities
Geron's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Geron's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Geron's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Geron's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Geron’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Geron stock
What were the liabilities of Geron compared to the previous year?
The liabilities of Geron have increased by 32.12% increased compared to the previous year.
What are the consequences of high debt for investors of Geron?
High liabilities can pose a risk for investors of Geron, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Geron?
Low liabilities mean that Geron has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Geron affect the company?
An increase in liabilities of Geron can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Geron affect the company?
A decrease in the liabilities of Geron can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Geron?
Some factors that can influence the liabilities of Geron include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Geron so important for investors?
The liabilities of Geron are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Geron take to modify the liabilities?
To change its liabilities, Geron can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Geron pay?
Over the past 12 months, Geron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geron is expected to pay a dividend of 0 USD.
What is the dividend yield of Geron?
The current dividend yield of Geron is .
When does Geron pay dividends?
Geron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geron?
Geron paid dividends every year for the past 0 years.
What is the dividend of Geron?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geron located?
Geron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geron from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.
When did Geron pay the last dividend?
The last dividend was paid out on 7/16/2024.
What was the dividend of Geron in the year 2023?
In the year 2023, Geron distributed 0 USD as dividends.
In which currency does Geron pay out the dividend?
The dividends of Geron are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Geron stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Geron
Our stock analysis for Geron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
